

Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on February 26, 2025, based on a complaint filed on behalf of Razor USA LLC of Cerritos, California and Shane Chen of Camas, Washington (collectively, "Complainants"). 90 FR 10,730 (Feb. 26, 2025). The complaint, as amended, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain motorized self-balancing vehicles by reason of the infringement of certain claims of U.S. Patent No. RE46,964; U.S. Patent No. RE49,608; and U.S. Patent No. D739,906. *Id.* The complaint further alleges that an industry in the United States exists or is in the process of being established as required by the applicable Federal Statute. *Id.* The Commission's notice of investigation named five respondents: Golabs Inc. d/b/a Gotrax of Carrollton, Texas; Dongguan Saibotan Nengyuan Keji Co., Ltd. d/b/a "Gyroor US" of Guangdong, China; Gyroor Technology (CHINA) Co., Ltd. d/b/a Gyroor of Guangdong, China; Shenzhen Chitado Technology Co., Ltd. d/b/a Gyroor of Guangdong, China; and Unicorn Network, LLC. d/b/a Sisigad ("Sisigad") of Dover, Delaware. *Id.*

Respondent Sisigad has been found in default. Order No. 7 (Apr. 16, 2025), *unreviewed* by Comm'n Notice (May 5, 2025).

On April 30, 2025, Complainants filed an unopposed motion to amend the complaint and NOI by adding a new respondent, Tao Motor, of Lishui City, China. The motion argued that good cause exists to add Tao Motor as a respondent and there is no prejudice to any party or the public interest by adding Tao Motor to the investigation.

On May 13, 2025, the ALJ issued the subject ID (Order No. 10), finding good cause to grant Complainants' unopposed motion to amend the complaint and NOI by adding Tao Motor. The ALJ found there is good cause to add Tao Motor as a respondent to this investigation and that the amendments will not prejudice

any of the parties or the public interest. Order No. 10 at 2. No petitions for review were filed.

The Commission has determined not to review the subject ID. Accordingly, Tao Motor is hereby added as a respondent to this investigation.

The Commission vote for this determination took place on June 3, 2025.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part 210 of the Commission's Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

Issued: June 4, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025-10393 Filed 6-6-25; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1356]

Certain Dermatological Treatment Devices and Components Thereof; Notice of a Commission Determination Finding a Violation of Section 337 as to Four Asserted Patents; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Remand of The Investigation as to One Asserted Patent; Extension of the Target Date

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has found a violation of section 337 and has determined to issue: a limited exclusion order prohibiting the unlicensed importation of certain dermatological treatment devices and components thereof that infringe one or more of claims 1, 9, and 22 of U.S. Patent No. 9,480,836 ("the '836 patent"); claims 11 and 16 of U.S. Patent No. 9,320,536 ("the '536 patent"); claim 14 of U.S. Patent No. 9,775,774 ("the '774 patent"); and claims 5, 13, and 18 of U.S. Patent No. 10,869,812 ("the '812 patent"); cease and desist orders against Respondents EndyMed Medical Ltd. of Caesarea, Israel; EndyMed Medical, Ltd. of New York, New York; and EndyMed Medical, Inc. of Freehold, New Jersey (collectively, "EndyMed"); and set a bond in the amount of eighty-five percent (85%) of the entered value of the EndyMed Pure, and seventy percent (70%) of the entered value of the

EndyMed Pro infringing products imported during the period of Presidential review. The investigation is terminated with respect to these four patents. The Commission has also determined to reverse the presiding administrative law judge's ("ALJ") finding that asserted claims 4, 6, and 7 of U.S. Patent No. 11,406,444 ("the '444 patent") are indefinite, remand the investigation to the ALJ with respect to that patent consistent with the concurrently issued Commission opinion and remand order, and extend the target date for completion of the investigation.

FOR FURTHER INFORMATION CONTACT:

Panyin A. Hughes, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-3042. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on April 6, 2023, based on a complaint filed by Serendia, LLC of Lake Forest, California ("Serendia"). 88 FR 20551-52 (Apr. 6, 2023). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain dermatological treatment devices and components thereof by reason of infringement of claims 1, 2, 5, 6, 9-14, 16, 17, 19, and 22 of the '836 patent; claims 1-5, 7-10, and 15 of U.S. Patent No. 10,058,379; claims 1-10 of the '444 patent; claims 1, 2, 4, 5, 8, 9, 11-13, 16, and 17 of the '536 patent; claims 1 and 6-15 of the '774 patent; and claims 1, 5-7, 9, 10, and 12-19 of the '812 patent. *Id.* at 20551. The complaint further alleges that a domestic industry exists. *Id.* The Commission's notice of investigation named as respondents Sung Hwan E&B Co., LTD. d/b/a SHENB Co. LTD of Seoul, Republic of Korea; Aesthetics Biomedical, Inc. of Phoenix, Arizona; Cartessa Aesthetics, LLC of Melville, New York; Lutronic Corporation of Goyang-si, Republic of

Korea; Lutronic Aesthetics, Inc., also known as Lutronic, Inc. of Billerica, Massachusetts; Lutronic, LLC of Billerica, Massachusetts; Ilooda, Co., Ltd. of Anyang-si, Republic of Korea; Cutera, Inc. of Brisbane, California; Rohrer Aesthetics, LLC of Homewood, Alabama; Rohrer Aesthetics, Inc. of Homewood, Alabama; Jeisys Medical Inc. of Seoul, Republic of Korea (“Jeisys”); Cynosure, LLC of Westford, Massachusetts (“Cynosure”); and EndyMed. *Id.* at 20552. The Office of Unfair Import Investigations (“OUII”) is also participating in the investigation. *Id.*

The Commission subsequently terminated the investigation as to all asserted patent claims except for claims 1, 9, and 22 of the ’836 patent; claims 11 and 16 of the ’536 patent; claim 14 of the ’774 patent; claims 5, 13, and 18 of the ’812 patent; and claims 4, 6, and 7 of the ’444 patent. *See* Order No. 16 (June 29, 2023), *unreviewed by* Comm’n Notice (July 20, 2023); Order No. 27 (Sept. 25, 2023), *unreviewed by* Comm’n Notice (Oct. 16, 2023); Order No. 43 (Nov. 8, 2023), *unreviewed by* Comm’n Notice (Dec. 12, 2023).

The Commission also subsequently terminated the investigation as to all respondents except for EndyMed. *See* Order No. 26 (Sept. 18, 2023), *unreviewed by* Comm’n Notice (Oct. 16, 2023); Order No. 38 (Oct. 27, 2023), *unreviewed by* Comm’n Notice (Nov. 20, 2023); Order No. 45 (Nov. 15, 2023), *unreviewed by* Comm’n Notice (Dec. 15, 2023); Order No. 47 (Nov. 20, 2023), *unreviewed by* Comm’n Notice (Dec. 15, 2023); Order No. 53 (Apr. 11, 2024), *unreviewed by* Comm’n Notice (May 8, 2024); Order No. 51 (Dec. 13, 2023), *unreviewed by* Comm’n Notice (Jan. 10, 2024); Order No. 64 (Dec. 18, 2024), *unreviewed by* Comm’n Notice (Jan. 17, 2025).

The ALJ held a *Markman* hearing on July 13, 2023, and issued a *Markman* Order on October 25, 2023, construing certain disputed claim terms. Order No. 35 (Oct. 25, 2023). The ALJ found the pending claims of the ’444 patent, claims 4, 6, and 7, indefinite in the *Markman* Order and did not consider those claims any further in the investigation. *Markman* (Order No. 35) at 62.

The ALJ held an evidentiary hearing on November 1–2, 6–7, 2023 and December 11–12, 2023, and received post-hearing briefs thereafter. Remaining in the investigation at that time were respondents EndyMed, Jeisys, and Cynosure and claims 1, 9, and 22 of the ’836 patent; claims 11 and 16 of the ’536 patent; claim 14 of the ’774

patent; and claims 5, 13, and 18 of the ’812 patent.

On December 19, 2024, the ALJ issued the final initial determination (“ID”) in this investigation finding a violation of section 337 as to claims 1, 9, and 22 of the ’836 patent; claims 11 and 16 of the ’536 patent; claim 14 of the ’774 patent; and claims 5, 13, and 18 of the ’812 patent by respondents EndyMed, Jeisys, and Cynosure. The ID found that by appearing and participating in the investigation, the parties consented to personal jurisdiction at the Commission. ID at 13. The ID found the importation requirement under 19 U.S.C.

1337(a)(1)(B) satisfied and that the Commission has *in rem* jurisdiction, noting that “[t]he Private Parties entered stipulations with respect to the importation of Accused Products wherein each Respondent stipulated that they have imported to the United States, sold for importation into the United States, and/or sold within the United States after importation at least one Accused Product.” *Id.* The ID found that Serendia has the exclusive rights and ownership in the Asserted Patents and thus has “standing” to assert the patents in this investigation. *Id.* at 23. The ID further found that Serendia successfully proved that the accused products directly infringe the Asserted Claims. ID at 70–88, 173–184, 216–225. The ID further found that EndyMed also indirectly infringes the asserted claims of the ’836 and ’536 patents via inducement and contributory infringement. ID at 97–104, 185–188. The ID found that EndyMed failed to show that the Asserted Claims are invalid for obviousness (ID at 120–145, 209–216, 230–232, 257–267). The ID found that EndyMed also failed to show that the asserted claims of the ’536 patent are invalid for anticipation (ID at 196–209) and also failed to prove that the asserted claims of the ’836 patent are invalid for lack of enablement (ID at 146–161), lack of written description support (ID at 161–167), or recite unpatentable subject matter under section 101 (ID at 167–173). The ID found the existence of a domestic industry that practices the Asserted Patents as required by 19 U.S.C. 1337(a)(2). ID at 104–110, 189–196, 226–230, 247–256, 267–300. Accordingly, the ID found a violation of section 337 as to four of the remaining five patents.

The ID included the ALJ’s recommended determination on remedy and bonding (“RD”). The RD recommended, should the Commission find a violation, issuance of a limited exclusion order and cease and desist orders against EndyMed. ID/RD at 302–

111. Regarding the amount of bond to be imposed during the period of Presidential review, the ID recommended that “the Commission enter a bond in the amount of 85% of the price of value EndyMed Pure product and 70% of the value of the EndyMed Pro product during the PRP [period of Presidential review].” *Id.* at 314.

Regarding Jeisys and Cynosure, the ID noted that they have been terminated from the investigation by the ALJ, but that given the timing of the termination, the analyses pertaining to them contained in the ID would not be deleted. ID at ii n.1. The ID stated that once the Commission addresses the ID terminating them, “Jeisys and Cynosure are no longer parties in this Investigation,” and their “accused products will no longer be at issue in this Investigation and will not be subject to any determinations set forth in the ID.” *Id.*; Order No. 64 (Dec. 18, 2024) (terminating Jeisys and Cynosure from the investigation), *unreviewed by* Comm’n Notice (Jan. 17, 2025).

On January 2, 2025, Jeisys and Cynosure filed a petition for review, asking the Commission to set aside the findings in the ID pertaining to them because of their termination from the investigation.

January 10, 2025, Serendia and EndyMed filed respective petitions for review of the ID. On January 21, 2025, the parties, including OUII, filed responses to the petitions.

On February 28, 2025, the Commission determined to review the final ID in part. 90 FR 11433–36 (Mar. 6, 2023). Specifically, the Commission determined to review the final ID’s findings on jurisdiction, standing, economic prong of domestic industry for all five patents, contributory infringement for the asserted claims of the ’536, ’774, ’812, and ’836 patents, secondary considerations for the ’536 and ’836 patents, and indefiniteness of the asserted claims of the ’444 patent. The Commission requested briefing on certain issues under review and on remedy, the public interest, and bonding. *Id.*

In its notice of review, the Commission vacated the findings in the ID pertaining to Jeisys and Cynosure due to their termination from the investigation. 90 FR 11435 (Mar. 6, 2023).

On March 14, 2025, the parties filed initial submissions in response to the Commission’s request for briefing. On March 21, 2025, the parties filed reply submissions.

Upon review of the parties’ submissions, the ID, the RD, evidence of

record, and the public interest, the Commission has determined that EndyMed violated section 337 by reason of importation and sale of articles that infringe asserted claims 1, 9, and 22 of the '836 patent; claims 11 and 16 of the '536 patent; claim 14 of the '774 patent; and claims 5, 13, and 18 of the '812 patent. Regarding the issues under review, the Commission has determined to (1) provide the modification in the accompanying Commission opinion for the ID's findings on jurisdiction and standing, (2) affirm the ID's findings on the economic prong of domestic industry for the reasons provided in the ID as supplemented in the opinion, (3) take no position on the ID's contributory infringement finding, (4) affirm the ID's findings on secondary considerations for the reasons provided in the ID, and (5) reverse and remand the ID's indefiniteness finding of the asserted claims of the '444 patent.

For the '444 patent, the Commission has determined to remand to the ALJ for further proceedings consistent with the Commission's opinion and remand order. The target date is extended to July 8, 2025. For remedy, the Commission has determined to issue a limited exclusion order prohibiting further importation of infringing products and cease and desist orders against EndyMed. The Commission has also determined that the public interest factors enumerated in paragraphs 337(d)(1) and (f)(1) (19 U.S.C. 1337(d)(1), (f)(1)) do not preclude the issuance of these remedial orders. The Commission has determined to set a bond in the amount of eighty-five percent (85%) of the entered value of the EndyMed Pure, and seventy percent (70%) of the entered value of the EndyMed Pro, for infringing products imported during the period of Presidential review pursuant to 19 U.S.C. 1337(j). The Commission's orders were delivered to the President and to the United States Trade Representative on the day of their issuance.

The Commission vote for this determination took place on June 3, 2025. The investigation is hereby terminated with respect to the '836, '536, '774, and '812 patents. The '444 patent is remanded to the ALJ. The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: June 3, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025-10394 Filed 6-6-25; 8:45 am]

BILLING CODE 7020-02-P

JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES

Meeting of the Advisory Committee; Meeting

AGENCY: Joint Board for the Enrollment of Actuaries.

ACTION: Notice of Federal Advisory Committee meeting.

SUMMARY: The Joint Board for the Enrollment of Actuaries gives notice of a teleconference meeting of the Advisory Committee on Actuarial Examinations (a portion of which will be open to the public) on July 10-11, 2025.

DATES: Thursday, July 10, 2025, from 10:00 a.m. to 6:00 p.m. (ET), and Friday, July 11, 2025, from 10:00 a.m. to 4:00 p.m. (ET).

ADDRESSES: The meeting will be held by teleconference.

FOR FURTHER INFORMATION CONTACT: Elizabeth Van Osten, Designated Federal Officer, Advisory Committee on Actuarial Examinations, at 202-317-3648 or elizabeth.j.vanosten@irs.gov.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Advisory Committee on Actuarial Examinations will meet by teleconference on Thursday, July 10, 2025, from 10:00 a.m. to 6:00 p.m. (ET), and Friday, July 11, 2025, from 10:00 a.m. to 4:00 p.m. (ET).

The purpose of the meeting is to discuss topics and questions that may be recommended for inclusion on future Joint Board examinations in actuarial mathematics and methodology referred to in 29 U.S.C. 1242(a)(1)(B) and to review the May 2025 Basic (EA-1) and Pension (EA-2L) Examinations in order to make recommendations relative thereto, including the minimum acceptable pass score. Topics for inclusion on the syllabus for the Joint Board's examination program for the November 2025 Pension (EA-2F) Examination also will be discussed.

A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. 1009(d), that the portions of the meeting dealing with the discussion of questions that may appear on the Joint Board's examinations and the review of the May 2025 Basic (EA-1) and Pension (EA-2L) Examinations fall within the exceptions to the open meeting requirement set

forth in 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such portions be closed to public participation.

The portion of the meeting dealing with the discussion of the other topics will commence at 2:30 p.m. (ET) on July 10, 2025, and will continue for as long as necessary to complete the discussion, but not beyond 3:30 p.m. (ET). Time permitting, after the close of this discussion by Advisory Committee members, interested persons may make statements germane to this subject. Persons wishing to make oral statements should contact the Designated Federal Officer at NHQJBEA@IRS.GOV and include the written text or outline of comments they propose to make orally. Such comments will be limited to 10 minutes in length. Persons who wish to attend the public session should contact the Designated Federal Officer at NHQJBEA@IRS.GOV to obtain teleconference access instructions.

Notifications of intent to make an oral statement or to attend the meeting must be sent electronically to the Designated Federal Officer by no later than July 3, 2025. In addition, any interested person may file a written statement for consideration by the Joint Board and the Advisory Committee by sending it to NHQJBEA@IRS.GOV.

Dated: June 4, 2025.

Thomas V. Curtin,

Executive Director, Joint Board for the Enrollment of Actuaries.

[FR Doc. 2025-10409 Filed 6-6-25; 8:45 am]

BILLING CODE 4830-01-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Ron Dunchok, M.D.; Decision and Order

On October 15, 2024, the Drug Enforcement Administration (DEA or Government) issued an Order to Show Cause (OSC) to Ron Dunchok, M.D., of San Dimas, CA (Registrant). Request for Final Agency Action (RFAA), Exhibit (RFAAX) 1, at 1, 3. The OSC proposed the revocation of Registrant's Certificate of Registration No. BD0178081, alleging that Registrant's registration should be revoked because Registrant is "currently without authority to handle controlled substances in the State of California, the state in which [he is] registered with DEA." *Id.* at 1-2 (citing 21 U.S.C. 824(a)(3)).

The OSC notified Registrant of his right to file with DEA a written request for hearing, and that if he failed to file such a request, he would be deemed to